Regenicin (Regenicin) Dividend Payout Ratio : 0.00 (As of Mar. 2023)

View and export this data going back to 2008. Start your Free Trial

What is Regenicin Dividend Payout Ratio?

Regenicin's dividend payout ratio for the months ended in Mar. 2023 was 0.00.

The historical rank and industry rank for Regenicin's Dividend Payout Ratio or its related term are showing as below:

RGIN's Dividend Payout Ratio is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.435
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2024-05-25), the Dividend Yield % of Regenicin is 0.00%.

Regenicin's Dividends per Share for the months ended in Mar. 2023 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Regenicin Dividend Payout Ratio Historical Data

The historical data trend for Regenicin's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regenicin Dividend Payout Ratio Chart

Regenicin Annual Data

Trend

Sep13

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Dividend Payout Ratio

Get a 7-Day Free Trial

Regenicin Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Dividend Payout Ratio	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Regenicin's Dividend Payout Ratio

For the Biotechnology subindustry, Regenicin's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regenicin's Dividend Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regenicin's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where Regenicin's Dividend Payout Ratio falls into.

Regenicin Dividend Payout Ratio Calculation

Dividend payout ratio measures the percentage of the company's earnings paid out as dividends.

Regenicin's Dividend Payout Ratio for the fiscal year that ended in Sep. 2022 is calculated as

Dividend Payout Ratio	=	Dividends per Share (A: Sep. 2022 )	/	EPS without NRI (A: Sep. 2022 )
	=	0	/	-0.004
	=	N/A

Regenicin's Dividend Payout Ratio for the quarter that ended in Mar. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Mar. 2023 )	/	EPS without NRI (Q: Mar. 2023 )
	=	0	/	-0.002
	=	N/A

Regenicin (OTCPK:RGIN) Dividend Payout Ratio Explanation

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

Regenicin Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of Regenicin's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Regenicin (Regenicin) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regenicin Inc (OTCPK:RGIN) » Definitions » Dividend Payout Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

10 High Court, Little Falls, NJ, USA, 07424

Website

https://www.regenicin.com

Regenicin Inc is a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs. Its skin substitute product candidate comprises of NovaDerm. NovaDerm is a multi-layered tissue-engineered living skin prepared by utilizing autologous (patient's own) skin cells. It is a graftable cultured epithelium skin substitute containing both epidermal and dermal components with a collagen base. The technology has been clinically tested in Hundreds of pediatric, catastrophic burn patients.

Regenicin (Regenicin) Headlines

No Headlines